Share This Author
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 months in the PCB group, and freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received.
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
Treatment with ubiquinone was associated with reversal of lovastatin-induced myopathy, and its prophylactic administration prevented the development of this toxicity in a cohort of 56 patients.
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
The results of this first clinical trial of a signal transduction inhibitor in patients with acute leukemias suggest that inhibitors of FT may have important clinical antileukemic activity.
O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
The pharmacokinetics (PK) was characterized and the dose level with prospectively defined dose-limiting toxicity in less than one third of patients by day 29 was considered tolerable, and the following empiric sorafenib starting doses by cohort were recommended.
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.
- A. Venook, M. Egorin, M. Ratain
- Medicine, BiologyJournal of clinical oncology : official journal…
- 14 July 2000
If gemcitabine is used for patients with elevations in AST level, no dose reduction is necessary, and patients with elevated bilirubin levels have an increased risk of hepatic toxicity, and a dose reduce is recommended.
Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473.
The maximum tolerated dose found is considerably higher than anticipated and the observation of a modification of the lipids of leukemic cells, serum, and blood in a patient with chronic leukemia provides a biochemical basis for a possible effect of fish oil supplements on cancer cachexia and tumor growth.
Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells.
A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients
Genistein displayed a possible bimodal effect (more effective at the lower dose) on bladder cancer tissue EGFR phosphorylation that should be evaluated further, possibly in combination with other agents.